Iterum Therapeutics (ITRM) Revenue & Revenue Breakdown
Iterum Therapeutics Revenue Highlights
Iterum Therapeutics Revenue by Period
Iterum Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | -100.00% |
| 2019-12-31 | $37.00K | -95.74% |
| 2018-12-31 | $869.00K | 71.06% |
| 2017-12-31 | $508.00K | 100.00% |
| 2016-12-31 | - | - |
Iterum Therapeutics generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Iterum Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $2.62M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | -100.00% |
| 2019-03-31 | $37.00K | -84.52% |
| 2018-12-31 | $239.00K | -5.91% |
| 2018-09-30 | $254.00K | 37.30% |
| 2018-06-30 | $185.00K | -3.14% |
| 2018-03-31 | $191.00K | -45.27% |
| 2017-12-31 | $349.00K | 119.50% |
| 2017-09-30 | $159.00K | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
Iterum Therapeutics generated - in revenue during Q1 2024, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Iterum Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ONTX | Traws Pharma | $226.00B | $56.00K |
| FBIO | Fortress Biotech | $59.66M | $13.03M |
| OCUP | Ocuphire Pharma | $19.05M | - |
| JAGX | Jaguar Health | $9.76M | $2.72M |
| TNXP | Tonix Pharmaceuticals | $7.77M | $2.21M |
| VRCA | Verrica Pharmaceuticals | $5.12M | $3.83M |
| AEZS | Aeterna Zentaris | $4.58M | $3.98K |
| EYEN | Eyenovia | $3.79K | $4.99K |
| GRTX | Galera Therapeutics | - | - |
| REVB | Revelation Biosciences | - | - |
| FWBI | Entero Therapeutics | - | - |
| ADIL | Adial Pharmaceuticals | - | - |
| DRMA | Dermata Therapeutics | - | - |
| HOTH | Hoth Therapeutics | - | - |
| VINC | Vincerx Pharma | - | - |
| CTXR | Citius Pharmaceuticals | - | - |
| CFRX | ContraFect | - | - |
| ITRM | Iterum Therapeutics | - | - |
| DFFN | CervoMed | - | - |
| ACST | Acasti Pharma | - | - |
ITRM Revenue FAQ
What is Iterum Therapeutics’s yearly revenue?
Iterum Therapeutics's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. ITRM's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Iterum Therapeutics’s quarterly revenue?
Iterum Therapeutics's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $2.62M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022). ITRM's quarterly revenue for Q3 2023 was $0, a 100.00% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022).
What is Iterum Therapeutics’s revenue growth rate?
Iterum Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was -100.00%.